Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 13 studies | 42% ± 21% | |
oligodendrocyte precursor cell | 8 studies | 29% ± 12% | |
adipocyte | 8 studies | 30% ± 6% | |
GABAergic neuron | 7 studies | 45% ± 23% | |
type I pneumocyte | 7 studies | 26% ± 7% | |
glutamatergic neuron | 6 studies | 40% ± 20% | |
retina horizontal cell | 5 studies | 35% ± 10% | |
retinal cone cell | 5 studies | 40% ± 11% | |
retinal rod cell | 5 studies | 31% ± 4% | |
Mueller cell | 5 studies | 21% ± 4% | |
oligodendrocyte | 5 studies | 24% ± 8% | |
endothelial cell | 4 studies | 33% ± 12% | |
fibroblast | 4 studies | 28% ± 11% | |
endothelial cell of lymphatic vessel | 4 studies | 18% ± 1% | |
interneuron | 4 studies | 52% ± 22% | |
neuron | 3 studies | 26% ± 9% | |
GABAergic interneuron | 3 studies | 27% ± 6% | |
granule cell | 3 studies | 26% ± 7% | |
retinal bipolar neuron | 3 studies | 21% ± 2% | |
OFF-bipolar cell | 3 studies | 30% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 9938.50 | 2642 / 2642 | 100% | 51.57 | 703 / 705 |
prostate | 98% | 2089.90 | 239 / 245 | 100% | 15.39 | 501 / 502 |
thymus | 99% | 4043.29 | 649 / 653 | 87% | 7.02 | 525 / 605 |
ovary | 100% | 4018.35 | 180 / 180 | 80% | 5.06 | 342 / 430 |
adrenal gland | 100% | 3716.74 | 258 / 258 | 64% | 6.67 | 148 / 230 |
breast | 100% | 3637.83 | 457 / 459 | 64% | 3.30 | 710 / 1118 |
uterus | 99% | 2332.18 | 168 / 170 | 47% | 3.08 | 216 / 459 |
bladder | 100% | 1841.24 | 21 / 21 | 40% | 1.73 | 201 / 504 |
lung | 89% | 1693.63 | 512 / 578 | 51% | 2.55 | 584 / 1155 |
stomach | 77% | 1255.25 | 276 / 359 | 42% | 3.00 | 121 / 286 |
kidney | 54% | 840.21 | 48 / 89 | 64% | 2.87 | 578 / 901 |
skin | 67% | 1723.69 | 1220 / 1809 | 48% | 4.00 | 227 / 472 |
esophagus | 69% | 1261.07 | 993 / 1445 | 44% | 2.43 | 81 / 183 |
adipose | 100% | 3874.90 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 2646.40 | 1325 / 1335 | 0% | 0 | 0 / 0 |
intestine | 69% | 1207.99 | 666 / 966 | 28% | 1.67 | 149 / 527 |
eye | 0% | 0 | 0 / 0 | 88% | 5.52 | 70 / 80 |
pancreas | 20% | 209.72 | 64 / 328 | 57% | 2.27 | 102 / 178 |
liver | 29% | 334.07 | 65 / 226 | 43% | 2.06 | 176 / 406 |
heart | 68% | 1025.32 | 588 / 861 | 0% | 0 | 0 / 0 |
spleen | 51% | 667.58 | 124 / 241 | 0% | 0 | 0 / 0 |
muscle | 48% | 573.61 | 387 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 17% | 1.83 | 5 / 29 |
tonsil | 0% | 0 | 0 / 0 | 9% | 0.43 | 4 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0014003 | Biological process | oligodendrocyte development |
GO_0030032 | Biological process | lamellipodium assembly |
GO_0030041 | Biological process | actin filament polymerization |
GO_0007010 | Biological process | cytoskeleton organization |
GO_0065003 | Biological process | protein-containing complex assembly |
GO_0030036 | Biological process | actin cytoskeleton organization |
GO_0098885 | Biological process | modification of postsynaptic actin cytoskeleton |
GO_2000601 | Biological process | positive regulation of Arp2/3 complex-mediated actin nucleation |
GO_0008360 | Biological process | regulation of cell shape |
GO_0031643 | Biological process | positive regulation of myelination |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0005856 | Cellular component | cytoskeleton |
GO_0070062 | Cellular component | extracellular exosome |
GO_0098794 | Cellular component | postsynapse |
GO_0097386 | Cellular component | glial cell projection |
GO_0030027 | Cellular component | lamellipodium |
GO_0031209 | Cellular component | SCAR complex |
GO_0034237 | Molecular function | protein kinase A regulatory subunit binding |
GO_0071933 | Molecular function | Arp2/3 complex binding |
GO_0003779 | Molecular function | actin binding |
Gene name | WASF3 |
Protein name | Actin-binding protein WASF3 (Protein WAVE-3) (Verprolin homology domain-containing protein 3) (Wiskott-Aldrich syndrome protein family member 3) (WASP family protein member 3) Wiskott-Aldrich syndrome protein family member (WASP family protein member) |
Synonyms | WAVE3 hCG_29938 SCAR3 KIAA0900 |
Description | FUNCTION: Downstream effector molecules involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the control of cell shape. . FUNCTION: Downstream effector molecule involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Promotes formation of actin filaments. Part of the WAVE complex that regulates lamellipodia formation. The WAVE complex regulates actin filament reorganization via its interaction with the Arp2/3 complex. . FUNCTION: Downstream effector molecule involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Promotes formation of actin filaments. Part of the WAVE complex that regulates lamellipodia formation. The WAVE complex regulates actin filament reorganization via its interaction with the Arp2/3 complex. . |
Accessions | A0A590UJ74 Q9UPY6 ENST00000671038.1 Q5T8P4 ENST00000361042.8 [Q9UPY6-2] ENST00000335327.6 [Q9UPY6-1] |